Addition of relatlimab to nivolumab plus platinum-doublet chemo demonstrates improved clinical benefit in NSCLC

Patient reported outcomes for telisotuzumab vedotin in c-Met protein overexpressing EGFR WT nonsquamous NSCLC

Nivolumab plus ipilimumab improves efficacy versus standard of care in non-clear-cell renal cell carcinomas

Repeat immune checkpoint inhibitor therapy not recommended for aRCC

Status of anti BCMA therapy in myeloma

The promise of CAR T cell therapy for multiple myeloma

Multiple myeloma In Rwanda: The need for further research

Bladder cancer updates from the first half of 2024

Biomarkers, predictive and prognostic factors of resistance to immunotherapy

Updates from ASCO 2024 in gastrointestinal tumours

GIST tumours and soft tissue sarcomas

Hormonal receptor positive breast cancer adjuvant and metastatic indications